2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 Tsarkakewa ≥98.0% Olaparib Tsakanin Masana'antu
Babban Tsafta, Samar da Kasuwanci
Olaparib da Matsakaici masu alaƙa:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid CAS 763114-26-7
1- (Cyclopropylcarbonyl) Piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Sunan Sinadari | 2-Fluoro-5-Formylbenzonitrile |
| Makamantu | 3-Cyano-4-Fluorobenzaldehyde |
| Lambar CAS | 218301-22-5 |
| Lambar CAT | Saukewa: RF-PI451 |
| Matsayin Hannun jari | A cikin Hannun jari, Ma'aunin samarwa Har zuwa Ton |
| Tsarin kwayoyin halitta | C8H4FNO |
| Nauyin Kwayoyin Halitta | 149.12 |
| Matsayin narkewa | 80.0 zuwa 84.0 ℃ (lit.) |
| Solubility | Mai narkewa a cikin methanol |
| Alamar | Ruifu Chemical |
| Abu | Ƙayyadaddun bayanai |
| Bayyanar | Yellow zuwa Kashe-fari foda |
| Tsafta | ≥98.0% |
| Danshi (KF) | ≤0.50% |
| Jimlar ƙazanta | ≤2.0% |
| Matsayin Gwaji | Matsayin Kasuwanci |
| Amfani | Matsakaicin Olaparib (CAS: 763113-22-0) Mai hanawa PARP |
Kunshin: Bottle, Aluminum tsare jakar, Kwali Drum, 25kg / Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi.
2-Fluoro-5-Formylbenzonitrile (CAS: 218301-22-5) ana amfani dashi a cikin shirye-shiryen heterocyclic mahadi a matsayin masu hana PARP don amfani da likita.2-Fluoro-5-Formylbenzonitrile ana amfani dashi azaman matsakaici na Olaparib (CAS: 763113-22-0).Olaparib karamin mai hana kwayoyin halitta ne na PARP1/PARP2 (IC50: 5/1 nM) amma ba shi da tasiri a kan PARP tankyrase-1 (IC50: 1.5 µM).Olaparib (AZD-2281, sunan kasuwanci Lynparza) magani ne da aka amince da FDA don cutar kansa, wanda KuDOS Pharmaceuticals ya haɓaka kuma daga baya ta AstraZeneca.Yana da mai hanawa na PARP, yana hana poly ADP ribose polymerase (PARP), wani enzyme da ke cikin gyaran DNA. Yana aiki da ciwon daji a cikin mutanen da ke da maye gurbin BRCA1 ko BRCA2 na gado, wanda ya haɗa da wasu ciwon daji na ovarian, nono, da prostate.A cikin Disamba 2014, olaparib an amince da amfani da shi azaman wakili ɗaya ta EMA da FDA.Amincewar FDA tana cikin germline BRCA mutated (gBRCAm) ci gaban ciwon daji na kwai wanda ya sami layukan chemotherapy uku ko fiye da suka gabata.
